Ignite Creation Date:
2024-05-06 @ 9:28 AM
Last Modification Date:
2024-10-26 @ 12:15 PM
Study NCT ID:
NCT02997202
Status:
COMPLETED
Last Update Posted:
2024-03-15
First Post:
2016-12-01
Brief Title:
A Trial of the FMS-like Tyrosine Kinase 3 FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3Internal Tandem Duplication ITD Acute Myeloid Leukemia AML
Sponsor:
Astellas Pharma Global Development Inc
Organization:
Astellas Pharma Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-06-07
Start Date Type:
ACTUAL
Primary Completion Date:
2023-03-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-05-09
Completion Date Type:
ACTUAL
First Submit Date:
2016-12-01
First Submit QC Date:
December 15 2016
Study First Post Date:
2016-12-19
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
2024-02-28
Disp First Submit QC Date:
February 28 2024
Disp First Post Date:
2024-03-01
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2024-08-16
Last Update Post Date:
2024-03-15
Last Update Post Date Type:
ACTUAL